Eli Lilly & Co (LLY) Earnings Date & Reports

Key Takeaways

• Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up roughly 39% year over year and above Wall Street consensus estimates.
• Non-GAAP (adjusted) earnings per share reached $7.48, a 7% increase from $7.02 a year earlier, while reported diluted EPS from continuing operations came in at $7.22.
• Mounjaro revenue climbed 65% to $10.7 billion, and Zepbound revenue rose 48% to $5.3 billion on strong demand.
• Management raised full-year 2026 revenue guidance to a range of $91 billion to $92 billion, with a midpoint of $91.5 billion.
• Full-year adjusted EPS guidance was trimmed to $35.00–$36.00, largely reflecting $4.57 per share in acquired in-process research and development (IPR&D) charges.
• Shares advanced in early trading following the release as investors responded to the stronger-than-expected top line and raised outlook.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover timely trade ideas with Trending AI Robots.

Earnings Context and Why It Matters

Eli Lilly's third-quarter 2026 report is a key checkpoint for a company whose growth is increasingly defined by its diabetes and obesity franchise. The market has been watching closely whether blockbuster treatments Mounjaro and Zepbound can sustain their expansion while the company rolls out newer products such as Foundayo. Coming off a period of accelerating revenue growth, this quarter's results offered investors a clearer read on demand trends, pricing dynamics, and the financial impact of a heavy investment cycle in research, manufacturing, and business development. The report also carried implications for the broader weight-loss and metabolic-health industry, where Lilly competes with rivals for market share in one of biopharma's fastest-growing categories.

Reported Results

Eli Lilly posted third-quarter 2026 revenue of $24.4 billion, an increase of about 39% from $17.6 billion in the prior-year period and ahead of analyst consensus. Non-GAAP (non-Generally Accepted Accounting Principles) earnings per share came in at $7.48, up 7% from $7.02 a year earlier, while reported diluted EPS from continuing operations was $7.22 compared with $6.21 in the year-ago quarter. Net income rose to approximately $6.45 billion from $5.58 billion.

The growth was led by the metabolic franchise. Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew 48% to $5.3 billion, both driven by strong volume. Gross margin as a percentage of revenue expanded, and the company's non-GAAP performance margin—defined as gross margin less research, marketing, selling, and administrative expenses divided by revenue—reached 54.2%, up 5.9 percentage points year over year. The quarter also included roughly $900 million of benefits tied to milestone payments and favorable adjustments to rebate and discount estimates.

Management raised its full-year 2026 revenue outlook to $91 billion–$92 billion, up from a prior range of $85 billion–$87 billion. At the same time, full-year adjusted EPS guidance was lowered to $35.00–$36.00 from $35.50–$36.50, reflecting $4.57 per share of acquired IPR&D (payments for research assets without alternative future use) charges from recent business development activity.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while sharpening the research process. Explore the AI Screener to see how it can support your own market analysis.

Market Reaction and Investor Sentiment

Shares of Eli Lilly rose in premarket and early trading following the announcement, climbing several percentage points as investors focused on the top-line beat and the raised revenue outlook. The upward move reflected relief that demand for Mounjaro and Zepbound remained robust and that management saw enough momentum to lift its full-year sales forecast. Sentiment was tempered somewhat by the reduced adjusted EPS guidance, which stemmed primarily from non-recurring acquired IPR&D charges tied to business development rather than weakening operations. Heading into the report, expectations were high, and the market interpreted the results as confirmation that Lilly's core growth engine remains intact even as it absorbs heavy investment.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Lilly can sustain the volume growth in its diabetes and obesity portfolio while managing pricing pressure, particularly in international markets and in the U.S. as rebate dynamics evolve. The global rollout of Foundayo, the company's oral GLP-1 (glucagon-like peptide-1) treatment, is an important near-term catalyst, as is the progression of Retatrutide, a next-generation weight-loss candidate. Regulatory decisions and new indications across oncology, immunology, and neuroscience could also shape the growth narrative.

Cost and margin trends remain a focal point. Lilly is investing heavily in research and development, promotional activity for new launches, and a major expansion of manufacturing capacity in the U.S., all of which pressure near-term margins even as they support long-term growth. The impact of further business development deals and any associated IPR&D charges will also be worth monitoring, since these can swing reported and adjusted earnings quarter to quarter.

Finally, competitive dynamics in the metabolic-health market will matter. With rivals advancing their own treatments, the pace of patient uptake, market share, and pricing across Lilly's key products will be central to whether the company can build on this quarter's momentum without sacrificing profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations